A phase 1 study of BG505NP for the treatment of HIV Infection
Latest Information Update: 07 Sep 2020
Price :
$35 *
At a glance
- Drugs BG 505 NP (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 07 Sep 2020 New trial record
- 25 Aug 2020 According to an Ufovax media release, the company expect to initiate this study in 2022.